Multibagger Selection: GPT-5.6 Sol's picks
GPT-5.6 Sol picked CAPR, NTLA, BEAM, LUNR, RXRX with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | GPT-5.6 Sol |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | CAPR | — | 81% | — | — |
| 2 | NTLA | — | 84% | — | — |
| 3 | BEAM | — | 86% | — | — |
| 4 | LUNR | — | 83% | — | — |
| 5 | RXRX | — | 75% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +4.25% | +3.73% | 1.27x | 0 |
| 1 month | -13.44% | -12.47% | 1.39x | 0 |
The model's market view
The strongest 12-month multibagger setups I could verify are concentrated in small-cap biotechnology with binary regulatory or pivotal-clinical catalysts, plus one space-infrastructure company where backlog conversion could create an operating inflection. These are scenario candidates rather than predictions that 3x, 5x or 10x outcomes will occur.
Why each pick
CAPR
Capricor has the clearest near-term binary re-rating setup in the screened universe because a roughly $0.50 billion equity value sits immediately ahead of an FDA decision on deramiocel for Duchenne muscular dystrophy. HOPE-3 met its primary upper-limb-function endpoint, and the company submitted 24-month open-label extension data and additional analyses after the July advisory committee process. The setup is unusually asymmetric: approval could transform CAPR from a pre-revenue biotechnology company into a commercialization-stage asset with a substantially larger forward revenue base, while rejection would materially impair the thesis. The latest quote I could verify was a September 25 pre-market price of $8.76; the verified market-cap figure of $498.25 million is based on the September 24 regular-session valuation.
NTLA
Intellia combines a relatively modest approximately $1.70 billion equity value with a late-stage in-vivo gene-editing program that has already produced positive Phase 3 HAELO results. The company expects FDA acceptance of the lonvo-z BLA in the second half of 2026 and, if approved, plans a U.S. commercial launch in the first half of 2027. That creates a direct 12-month transition from clinical-stage valuation toward potential commercial-stage valuation. The ATTR franchise adds substantial optionality, although prior clinical holds and liver-safety observations materially increase risk. The latest quote I could verify was a September 25 pre-market price of $12.05; the $1.703 billion market capitalization is verified for September 24.
BEAM
Beam has one of the strongest balance sheets among sub-$5 billion gene-editing developers and multiple independent regulatory or clinical paths that could re-rate the company over the next year. BEAM-302 has moved into a global pivotal cohort after durable Phase 1/2 AATD data, while Beam expects a BLA submission for risto-cel as early as year-end 2026. Its approximately $1.15 billion June cash and securities balance represents almost half of the verified $2.46 billion market capitalization, reducing near-term financing pressure. The latest price I could verify was $24.65 in September 24 after-hours trading; I could not confirm a fresher September 25 trade from a reliable accessible quote, so I have retained the real date rather than relabeling it as current-day data.
LUNR
Intuitive Machines has a fundamentally different multibagger setup from the biotechnology names: revenue and contracted backlog are already scaling rapidly. Q2 2026 revenue reached $206 million, more than four times Q2 2025, and backlog ended June at approximately $1.8 billion versus $213 million at year-end 2025. New commercial satellite, lunar and national-security awards provide a documented route to further expansion. The challenge is valuation and dilution: at approximately $3.59 billion, a 3x outcome already requires the company to justify a valuation above $10 billion, while shares outstanding have risen sharply. The freshest quote I could verify was $16.00 in September 25 pre-market trading.
RXRX
Recursion offers a high-upside clinical-validation thesis rather than a near-term commercialization thesis. The company has already produced an efficacy signal with REC-4881 in familial adenomatous polyposis and has multiple clinical readouts scheduled through 2026 and 2027. Genentech's decision to advance the first neuroscience target from the companies' collaboration provides external validation that Recursion's AI-enabled discovery platform can generate actionable programs. The balance sheet provides runway into early 2028, but annual collaboration revenue remains small relative to the approximately $2.09 billion market capitalization. The latest price I could verify was $3.94 in September 24 after-hours trading; I could not verify a fresher September 25 trade from the accessible quote sources.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5.5 | INBX, CRML, LUNR, RDW, SRZN |
| Gemini 1.5 Pro | DLO, TBN, IRON, AGYS, VNDA |
| Muse Spark 1.1 | ENVA, SMR, RARE, CAPR, INDP |
| Perplexity | LQDA, AAOI, CRDO, RDW, POET |
| Grok 4.5 | AESI, SOUN, PRME, MYRG, VSEC |
| DeepSeek | QMLS, DUOT, TLSI, NUAI, OPTX |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.